Loading
collectionsCollection
National Brain Tumor Society (NBTS)
The National Brain Tumor Society is the largest US brain tumour nonprofit. It co-founded GBM AGILE, the adaptive platform trial that has enrolled more than 1,500 glioblastoma patients across several drug arms at once, funds research collaboratives, and lobbies the FDA on endpoints for brain tumours.
Overview
Formed 2008 (merger of the Brain Tumor Society and the National Brain Tumor Foundation). NBTS funds research collaboratives, co-founded the Global Coalition for Adaptive Research (GBM AGILE, which has enrolled >1,500 patients across regorafenib, paxalisib, VAL-083 and other arms, reporting the first results 2023-24), convenes the Brain Tumor Investment Fund, and leads advocacy (e.g. Head to the Hill, DIPG/DMG legislation). Patient resources include a personalised support and navigation programme.
Holds
Patient and caregiver resources, the GBM AGILE adaptive platform trial (co-founder via GCAR), the Defeat GBM and Defeat Pediatric Brain Tumors research collaboratives, policy advocacy and the Brain Tumor Registry initiatives.
Licence
Copyright NBTS
Maintainer
NBTS
Similar pages
- CollectionLymphoma Research Foundation (LRF)
Shares Primary CNS lymphoma and the tag patient-org.
- CollectionSt. Baldrick's Foundation
Shares Medulloblastoma and the tag patient-org.
- CollectionAlex's Lemonade Stand Foundation (ALSF)
Shares Medulloblastoma and the tag patient-org.
- CollectionPancreatic Cancer Action Network (PanCAN)
Shares Basket, umbrella, and platform trials and the tag patient-org.
- TargetHistone H3.3 (H3-3A)
- TrialACTION
- BiomarkerH3 K27M mutation
- TargetMGMT (O6-methylguanine-DNA methyltransferase)
cancers
drugs
ApprovedSmall-molecule imipridone (ClpP agonist / DRD2 antagonist)
Dordaviprone · Modeyso
ApprovedSmall-molecule IDH1/2 inhibitor
Vorasidenib · Voranigo